The management of anaemia in chronic kidney disease (CKD) patients is a complex, multifaceted process reliant on the administration of exogenous erythropoiesis stimulating agents (ESAs) and iron supplements to ensure the adequate production of viable
erythrocytes. Recommended best practice guidelines should be adhered to in order to ensure favourable treatment outcomes whilst
minimising the risks often associated with ESA therapy. A paucity in readily available, accurate data makes quantifying the extent
to which renal anaemia affects our population and how it is managed challenging, however it is expected to follow international
trends. Novel preparations for treating renal anaemia are currently in the clinical trial phase, therefore the potential benefits and risks
have yet to be confirmed.